1. Janssen’s Tremfya (guselkumab) Receives the US FDA’s Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis Published: Sept 10, 2020 | Tags: Janssen, Tremfya, Guselkumab, Biologic, US […]readmore
Tags : Redx
Shots: Redx is working on study including lower starting dose and enhanced safety monitoring, assessing safety and tolerability of drug in patients with advance malignancies Redx claims that RXC004 a […]readmore